Impact of obesity treatment on cardiometabolic health

Form Health provides overweight and obesity treatment that positively impacts cardiometabolic health outcomes, including improvements in glucose control, lipid levels, and blood pressure outcomes that not only benefit patients clinically but can contribute to Employer healthcare cost reduction by reducing long-term disease burden among covered lives.

Type 2 Diabetes: Mean Hemoglobin A1c improved from 9.0 to 6.2%, among those with the highest initial readings

Prediabetes (with Hemoglobin A1c ≥5.7%): 59% had normal Hemoglobin A1c at last measure

Hyperlipidemia: 57% Stopped lipid-lowering medications

Hypertension: 50% Stopped antihypertensive medications

Elevated Liver Enzymes: 52% Experienced normalization in elevated liver function tests.

Download the report to learn how Form Health total obesity and cardiometabolic care results in medical cost savings by improving, or even resolving, cardiometabolic conditions with weight loss.